| Trial ID: | L4784 |
| Source ID: | NCT01508923
|
| Associated Drug: |
Liraglutide
|
| Title: |
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: 24-hour glucose profiles after three fixed meals | Secondary: 24-hour insulin profiles after three fixed meals|First phase insulin and maximal insulin secretory capacity|EGR (endogenous glucose release) expressed in mg/kg/min|GNG (gluconeogenesis) expressed in mg/kg/min|24-hour glucagon profiles after three fixed meals|24-hour FFA (free fatty acids) profiles after three fixed meals|4-hour paracetamol profiles after two fixed meals|30-hour NNC 90-1170 profile|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
17
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2001-05
|
| Completion Date: |
2002-02
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-24
|
| Locations: |
Novo Nordisk Investigational Site, Århus C, 8000, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT01508923
|
